Cancer Treatments Opt Out Trials In Children: EU Regulations Gets Outdated

  • comments
  • print
  • email
Mar 11, 2017 09:00 PM EST

The outdated EU regulations opt out cancer treatment trials in children. The cancer experts urge the European officials to reform the regulation for timely cancer treatment for children.

The BBC NEWS has reported that The Institute of Cancer Research in London has pointed out that many children have died due to cancer as they were not permitted to trail the treatment on them. And soon there is a possibility for the alteration of EU regulations soon. The European Medicines Agency (EMA) set the EU Paediatric Regulation in 2007 curtailing the trail of cancer drugs in children.

The regulations were made to avoid the restrict the massive trial of newly invented cancer drugs on children. For different types of cancers, several medicines are formulated and changed. The drug companies want the trials to be worthwhile and several drugs are irrelevant or unsafe for children. And for this reason, the drug companies don't support the drugs to be trialed in children.

The Institute of Cancer Research and the research team are trying hard to bring the change in EU regulations. But it seems no such change in regulations is possible in the coming years. The ICR even requested for a lower age limit so that it will be possible to trials cancer drugs in adolescents.

Due to the outdated regulations, the children are missing out their chances of the latest cancer treatment. The authorities are pointing out the least possibility of children to have cancer as a reason to uphold the regulation.

There are several cases reported in which the children are dead due to rare cancer. Such conditions can be avoided in the future with the reformation of the regulations which restrict the trial of cancer drug on children. The cancer treatments have been updated in the recent years and the drugs have the potential to save the children with cancer. To know more about cancer in young people click here.
     

Join the Conversation
Real Time Analytics